Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
Key claim: A phase II single-arm trial is evaluating the efficacy and safety of selinexor (XPO1 inhibitor) in patients with primary or secondary myelofibrosis who are refractory or intolerant to ruxolitinib and/or other JAK1/2 inhibitors.
Abstract
This is a phase II, open label, prospective, single-arm study evaluating the efficacy and safety of selinexor in patients with PMF or secondary MF (PPV-MF or PET-MF) who are refractory or intolerant to ruxolitinib and/or any other experimental JAK1/2 inhibitors.
Why this matters
JAK-inhibitor failure (refractoriness or intolerance to ruxolitinib and other JAK1/2 inhibitors) defines one of the highest-unmet-need subpopulations in primary and secondary myelofibrosis, with no established standard of care. This trial extends selinexor — already advancing as a JAKi-combination partner in SENTRY and selinexor+pacritinib — into salvage monotherapy, joining AJ1-11095, flonoltinib, roginolisib+ruxolitinib, and fedratinib+nivolumab in the JAKi-refractory PMF (and post-PV/post-ET MF) therapeutic landscape. It also clarifies selinexor’s positioning across treatment lines: combination in JAKi-naïve disease versus monotherapy after JAKi failure.